On Friday, October 16, the FDA approved idarucizumab (Praxbind) as an effective reversal agent for the oral direct thrombin inhibitor, dabigatran (Pradaxa). Click here tor the press release. Thanks to Dr. Paul Riley, Stago-US, for this heads-up.
On Friday, October 16, the FDA approved idarucizumab (Praxbind) as an effective reversal agent for the oral direct thrombin inhibitor, dabigatran (Pradaxa). Click here tor the press release. Thanks to Dr. Paul Riley, Stago-US, for this heads-up.
